These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 580591)

  • 21. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum glycoside levels by rubidium assay.
    Ritzmann LW; Bangs CC; Coiner D; Custis JM; Walsh JR
    Arch Intern Med; 1973 Dec; 132(6):823-30. PubMed ID: 4757255
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)].
    Cano JP; Rigault JP; Gevaudan MJ; Saingra S; Murisasco A; Charpin J
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):335-9. PubMed ID: 6460972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical experience with the cardiac glycoside Gitoformat (author's transl)].
    Benda L; Zenz W
    Med Klin; 1978 Jul; 73(30):1081-4. PubMed ID: 672762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasma concentration and elimination behavior of the cardiac glycoside meproscillarin in patients with liver cirrhosis].
    Burkert K; Beckmann H
    Z Gastroenterol; 1983 Jan; 21(1):34-40. PubMed ID: 6845784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of nimodipine in normal and impaired renal function.
    Kirch W; Rämsch KD; Dührsen U; Ohnhaus EE
    Int J Clin Pharmacol Res; 1984; 4(5):381-4. PubMed ID: 6519852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A dosage regimen for epicillin in renal impairment (author's transl)].
    Humair L; Modde H; Kienel G
    Arzneimittelforschung; 1981; 31(4):722-5. PubMed ID: 7195720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative pharmacokinetics of the beta-1 receptor blookader celiprolol after a single oral administration in subjects with health kidneys and in patients with impaired renal function].
    Schmidt P; Takacs F; Pittner H; Minar E; Balcke P; Zazgornik J; Deutsch E
    Wien Klin Wochenschr; 1985 Sep; 97(18):729-32. PubMed ID: 2866633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F; Floridi AG; Floridi A; Buoncristiani U
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Concentration of cefadroxil in kidney tissue and serum after oral administration in patients with normal and impaired renal function].
    Degen J; Ringwelski L; Maier-Lenz H
    Arzneimittelforschung; 1983; 33(9):1339-42. PubMed ID: 6685518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum levels and kinetics of digoxin in patients with hyperthyroidism (author's transl)].
    Gaita F; Bocchiardo M; Brossa C; Molinatti GM; Rosettani E; Brusca A
    G Ital Cardiol; 1980; 10(7):836-42. PubMed ID: 7461331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Aug; 485():1-233. PubMed ID: 12571678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cimetidine pharmacokinetics after oral administration of cimetidine retard in normal and impaired renal function.
    Shaheen RA; Zazgornik J; Kuska J; Kokot F; Schneider J
    Int J Clin Pharmacol Ther Toxicol; 1990 Nov; 28(11):480-6. PubMed ID: 2272709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of nisoldipine in hypertensive patients with normal and mild to moderate impaired renal function.
    Shionoiri H; Minamisawa K; Masumori S; Satta H; Minamisawa M; Takizawa T; Jinno Y; Takeda K; Nagasawa T; Takasaki I
    Arzneimittelforschung; 1995 Jul; 45(7):785-9. PubMed ID: 8573223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of pefloxacin in normal and impaired renal function.
    Höffler D; Schäfer I; Koeppe P; Sörgel F
    Arzneimittelforschung; 1988 May; 38(5):739-43. PubMed ID: 3166377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Digitalis therapy in renal failure with special regard to digitoxin.
    Vöhringer HF; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):175-84. PubMed ID: 7021432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [86rb uptake by red cells (author's transl)].
    Yamane T; Fukuda N; Matsumoto T; Arai T
    Radioisotopes; 1980 Dec; 29(12):602-4. PubMed ID: 7244306
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.